Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)

13 slides from Abcellera Biologics's conference presentation, Jan 15, 2025

1. Slide 1: 43rd Annual J.P. Morgan Healthcare Conference

   43rd Annual J.P. Morgan Healthcare Conference COPYRIGHT © ABCELLERA January 15, 2025

2. Slide 2: Disclaimer

   DISCLAIMER 43rd Annual J.P. Morgan Healthcare Conference This presentation contains forward-looking statements, including statements made These statements involve risks, uncertainties and other factors that may cause pursuant to the safe harbor provisions of the Private Securities Litigation Reform

3. Slide 3: AbCellera is an early-stage biotech with integrated capabilities for antibody drug creation

   AbCellera is an early-stage biotech with integrated 43rd Annual J.P. Morgan Healthcare Conference capabilities for TECHNOLOGY antibody drug creation. TEAM THE ENGINE Our discovery engine combines computation, engineering, molecular design, and biology to support the internal discovery and developmen

4. Slide 4: Our engine was built through 10 years of drug discovery partnerships

   100+ 14 Our engine was built partnered-initiated molecules from partnered therapeutic programs* programs have reached the clinic* through 10 years of 43rd Annual J.P. Morgan Healthcare Conference New: TCE Deal drug discovery AbbVie partnerships. Since 2014, we have partnered with some of the industr

5. Slide 5: Partnerships have built a large portfolio of royalties in future antibody medicines

   Partnerships have built a large portfolio of royalties in future antibody medicines. 43rd Annual J.P. Morgan Healthcare Conference Cumulative # of Cumulative # of PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC* WITH DOWNSTREAMS* The value of this portfolio will mature over time as our part

6. Slide 6: Ramped down partnership business and focused on building internal pipeline

   Over the past year we have ramped down the partnership business and are focused on building a pipeline of internal programs. 43rd Annual J.P. Morgan Healthcare Conference Clinical manufacturing facility Clinical development of internal pipeline 12+ years Final large platform investments will be comp

7. Slide 7: We have the capabilities and the capital to execute on our strategy

   We have the ~$875M in available liquidity 43rd Annual J.P. Morgan Healthcare Conference to execute on capabilities and the our strategy* capital to execute on our strategy. ~$670M in total cash, cash equivalents, & marketable securities* Through our partnership work, revenue from COVID, and committe

8. Slide 8: We pursue high-value opportunities across multiple indications and modalities

   We pursue high-value Do we like the science? opportunities across 43rd Annual J.P. Morgan Healthcare Conference multiple indications Is there a commercial opportunity and modalities. with an unmet medical need? Our platform supports multiple modalities including IgGs, ADCs and bispecifics. Our strate

9. Slide 9: ABCL635 (undisclosed)

   ABCL635 (undisclosed) Science Commercial Opp Differentiation Development Path 43rd Annual J.P. Morgan Healthcare Conference • Pathway validated • High unmet need in • Potential first-in-class • Clear clinical with small molecules large target antibody in area of development path population metabolic

10. Slide 10: ABCL575 (OX40L antagonist)

    ABCL575 (OX40L antagonist) Science Commercial Opp Differentiation Development Path 43rd Annual J.P. Morgan Healthcare Conference • OX40L mechanism of • Atopic dermatitis is an • Competitive space with • Well-established clinical action established in $11B+* market, growing two late stage programs de

11. Slide 11: In 2025 we intend to submit CTAs for our first programs

    In 2025 we intend to submit CTAs* for our first 2 programs, and elect development candidates for 2 additional programs. 43rd Annual J.P. Morgan Healthcare Conference MOLECULE TARGET THERAPEUTIC AREA STAGE * Clinical Trial Applications (CTAs) = Canadian equivalent to an Investigational New Drug (IND)

12. Slide 12: Key milestones in the next 18-24 months

    2025 Q2 On-Track First 2 1-3 INDs 43rd Annual J.P. Morgan Healthcare Conference We expect a CTAs * per year number of for ABCL635, ABCL575 over next key milestones 5 years in the next 2026 ● 20+ internal programs First 2 in the pipeline 18-24 months. readouts ● Expect steady flow of readouts on poten

13. Slide 13: Thank You

    COPYRIGHT © ABCELLERA 13 43rd Annual J.P. Morgan Healthcare Conference THANK YOU

AbCellera Biologics — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix